Chest

1. BHATNAGAR M, Rahman NM
   "Not-So-Simple": Rethinking Pleural Effusions in Cancer, Heart Failure, and Pneumonia.
   Chest. 2025;168:290-291.
   

   >> Share

   
   

   
   Circ Heart Fail

2. SHOJI S, Fonarow GC, Greene SJ
   Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score.
   Circ Heart Fail. 2025 Aug 13:e013417. doi: 10.1161/CIRCHEARTFAILURE.125.013417.
   

   >> Share

   
   

   
   Circ Res

3. PALACIOS-MERINO J, Lara-Pezzi E
   Cutting Loose to Hold on: A Feedback Loop Between GPLD1 and uPAR in Heart Failure.
   Circ Res. 2025;137:584-586.
   

   >> Share

   
   

   
   Circulation

4. KORNELIUS E
   Letter by Kornelius Regarding Article, "Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure".
   Circulation. 2025;152:e63.
   

   >> Share

   
   

   
   Eur Heart J

5. CREA F
   Comprehensive update on heart failure and cardiomyopathies: from epidemiology to mechanisms and management.
   Eur Heart J. 2025;46:3027-3031.
   

   >> Share

   
   

   
   Eur J Heart Fail

6. STOCKER TJ, Geisler T, Rottbauer W, Lubos E, et al
   Rationale and design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) trial.
   Eur J Heart Fail. 2025 Aug 11. doi: 10.1002/ejhf.3795.
   

   >> Share

   
   
7. UDELSON JE, Goldsmith SR, Burkhoff D, Colorado P, et al
   A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial.
   Eur J Heart Fail. 2025 Aug 11. doi: 10.1002/ejhf.3801.
   

   >> Share

   
   
8. GREENE SJ, Sauer AJ, Bohm M, Bozkurt B, et al
   Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry.
   Eur J Heart Fail. 2025 Aug 11. doi: 10.1002/ejhf.3800.
   

   >> Share

   
   
9. MALGIE J, Wilde MI, Koudstaal S, Denham R, et al
   Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF.
   Eur J Heart Fail. 2025 Aug 14. doi: 10.1002/ejhf.70006.
   

   >> Share

   
   

   
   Int J Cardiol

10. HASUMI E, Fujiu K
    Reply to "Comments: Heart failure monitoring with a single-lead electrocardiogram at home".
    Int J Cardiol. 2025 Aug 6:133734. doi: 10.1016/j.ijcard.2025.133734.
    

    >> Share

    
    
11. ZHU B, Xu Y
    Expanding generalizability and addressing bias in mobile app-assisted heart failure screening.
    Int J Cardiol. 2025 Aug 7:133738. doi: 10.1016/j.ijcard.2025.133738.
    

    >> Share

    
    
12. HONG F, Sun B
    Comment on efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population.
    Int J Cardiol. 2025 Aug 7:133739. doi: 10.1016/j.ijcard.2025.133739.
    

    >> Share

    
    
13. HU Y, Zhang Y, Han P, Pan Y, et al
    Machine learning-driven prediction of readmission risk in heart failure patients with diabetes: synergistic assessment of inflammatory and metabolic biomarkers.
    Int J Cardiol. 2025;441:133743.
    

    >> Share

    
    
14. ZHU Y, Guo J
    Omics-driven strategy develops a tumor biomarker-derived signature to forecast the occurrence and progression of heart failure.
    Int J Cardiol. 2025 Aug 9:133742. doi: 10.1016/j.ijcard.2025.133742.
    

    >> Share

    
    
15. WANG Y
    Optimizing SGLT2 inhibitor continuation in super-aged heart failure.
    Int J Cardiol. 2025 Aug 9:133759. doi: 10.1016/j.ijcard.2025.133759.
    

    >> Share

    
    
16. NOIRI JI, Tanaka H
    Authors' reply to Hong et al. regarding "Efficacy of sodium glucose cotransporter 2 inhibitors for super aged heart failure population".
    Int J Cardiol. 2025 Aug 12:133783. doi: 10.1016/j.ijcard.2025.133783.
    

    >> Share

    
    
17. NOIRI JI, Tanaka H
    Authors' reply to Wang et al. regarding "Efficacy of sodium glucose cotransporter 2 inhibitors for super aged heart failure population".
    Int J Cardiol. 2025 Aug 12:133782. doi: 10.1016/j.ijcard.2025.133782.
    

    >> Share

    
    

    
    J Card Fail

18. 
    Supporting the Future of Heart Failure Care: HFSA's Benefits for Early Career and Trainee Members.
    J Card Fail. 2025;31:1374-1375.
    

    >> Share

    
    
19. BERG-HANSEN K, Tinggaard AB, Nielsen R, Jensen TH, et al
    Should exogenous ketone body supplementation be considered in patients hospitalized for acute heart failure? Rationale and design of the KETO-AHF trial.
    J Card Fail. 2025 Aug 9:S1071-9164(25)00333.
    

    >> Share

    
    
20. ALAM-SHOUSHTARI S, Hawkins NM, McKelvie R, Poon S, et al
    Time-to-Diuretics in Acute Heart Failure Management: Striking the Balance between "Speed" versus "Accuracy".
    J Card Fail. 2025 Aug 8:S1071-9164(25)00332.
    

    >> Share

    
    

    
    J Cardiol

21. OZAKI Y, Uemura Y, Kondo T, Kazama S, et al
    Hemodynamic integration of pulmonary artery pulsatility index and compliance for risk stratification in patients with heart failure with reduced ejection fraction.
    J Cardiol. 2025 Aug 6:S0914-5087(25)00204-7. doi: 10.1016/j.jjcc.2025.
    

    >> Share

    
    
22. FUJIMOTO W, Matsumoto S, Kanaoka K, Nasu T, et al
    Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.
    J Cardiol. 2025;86:202-208.
    

    >> Share

    
    

    
    PLoS One

23. LEDO APO, Matos SMA, Almeida MDCC, Aras R, et al
    Incidence and risk factors for heart failure in the ELSA-Brasil cohort.
    PLoS One. 2025;20:e0329113.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share